Literature DB >> 18172353

[Pathogenesis and treatment of intestinal Behçet's disease].

Chang-Kyun Lee1, Hyo-Jong Kim.   

Abstract

Intestinal Behçet's disease (BD) refers to colonic ulcerative lesions documented by objective measures in patients with BD. Although the causes of intestinal BD are unknown, genetic, environmental, and immunological factors have been suggested. Intestinal BD is common in BD patients from Far East, while it is uncommon in those from the Middle East. The reasons for such peculiar geographic distribution in intestinal BD are unknown, but may provide clues for the elucidation of putative etiological agents or genetic factors that might be associated with intestinal BD. Although the treatment of Crohn's disease has improved significantly during past decade, the treatment of intestinal BD is still problematic. Corticosteroids, sulfasalazine, immunomodulators, and colchicines have been used to treat intestinal BD with varying degree of success. Thalidomide and its analogues also appear to be applicable. Monoclonal antibodies to TNF-alpha have recently been focused as a novel therapeutic option for patients with intestinal BD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18172353

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  3 in total

Review 1.  Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.

Authors:  Yehyun Park; Jae Hee Cheon
Journal:  Curr Gastroenterol Rep       Date:  2020-03-19

2.  Subtotal colectomy for intestinal Behcet's disease: a histopathological surprise.

Authors:  Abhijit D Hiregoudar; Mukunda M Battal; N Vishwanath; S C Nadaf; Ravikala Rao; U S Dinesh
Journal:  Indian J Surg       Date:  2009-06-10       Impact factor: 0.656

Review 3.  Updated treatment strategies for intestinal Behçet's disease.

Authors:  Yong Eun Park; Jae Hee Cheon
Journal:  Korean J Intern Med       Date:  2017-12-08       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.